GCI Subsiduary PhytoPain Pharma Announces Submission of Orphan Drug Designation Application for Delta-9 …

OTTAWA, ONTARIO–(Marketwired – Sept. 6, 2016) – PhytoPain Pharma Inc. (“PhytoPain Pharma” or “PPP“), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company“) (CSE:GCI), today announces the submission to the US Food and Drug Administration (FDA) Office of Orphan Products Development, two applications for Orphan Drug Designation for delta-9-tetrahydrocannibinol and cannabidiol for the treatment of patients with Complex Regional Pain Syndrome Type 1 (CRPS1) and patients with Central PostStroke Pain (CPSP). The decision to proceed with these Orphan Drug Designation submissions is part of PPP’s plan to move forward with the development of a cannabis prescription drug product for the treatment of neuropathic pain associated with CRPS1 and CPSP. If successful, the designation of delta-9-tetrahydrocannibinol and cannabidiol as an Orphan Drug will open the door for many opportunities most notably tax credits on clinical research reduction of the waiting period and reduced registration fees. It also

... read more at: http://www.geologyforinvestors.com/gci-subsiduary-phytopain-pharma-announces-submission-of-orphan-drug-designation-application-for-delta-9-tetrahydrocannibinol-and-cannabidiol-in-the-united-states/

by